Print Send My Information

Purpose

The purpose of this study is to collect efficacy and safety information of intravitreal injection for 3 experimental arms, including 2 dose levels of ONL1204 and 2 treatment frequencies in patients with GA associated with AMD. GA associated with AMD is one of the world's leading causes of visual disability and legal blindness globally. Associated with aging, cigarette smoking, obesity, diets low in certain nutrients, a lifestyle related to cardiac risk, and a growing list of genetic factors, AMD is becoming an increasingly prevalent public health concern, especially as the global population ages. ONL1204 is a first-in-class inhibitor of fragment apoptosis stimulator receptor-mediated cell death that has demonstrated protection of multiple retinal cell types in numerous preclinical models of retinal disease, including models of dry AMD.

Conditions

Eligibility

Eligible Ages
Over 55 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. 55 years of age or older at Screening. 2. Able and willing to give informed consent and attend study visits. 3. Women or intersex individuals must be willing to use 2 forms of effective contraception during the study and for at least 90 days following the last dose of study drug, be postmenopausal for at least 12 months prior to study entry, or surgically sterile. If of childbearing potential, a negative urine pregnancy test is required at Screening and prior to the administration of study drug at each visit. 4. Men or intersex individuals with partners of childbearing potential must be willing to use permissible methods of contraception and refrain from sperm donation during the study and for at least 90 days following the last dose of study drug. 5. If currently using Age-related Eye Disease Study 2 (AREDS, AREDS2, or similar nutraceutical therapy at Screening, patient must be willing to continue use for the duration of the study. If not currently using AREDS2 or similar, patient must be willing to continue not to use therapy for the duration of the study. Patient must agree to choose either approach. Study Eye Inclusion Criteria: 6. BCVA of 24 letters or more using ETDRS charts in the study eye at Screening. 7. Intraocular pressure (IOP) of 22 mmHg or lower in the study eye at Screening. The GA lesion must meet all the following criteria: 8. Non-foveal GA associated with AMD without eMNV in the study eye per Investigator's evaluation and as confirmed by the central RC. 9. GA ≥0.85 disc area (DA) (2.125 mm2) and ≤8.05 DA (20.125 mm2) in the study eye as confirmed by the central RC. 10. If GA in the study eye is multifocal, at least 1 focal lesion must be ≥0.425 DA (1.063 mm2) as confirmed by the central RC. 11. Non-foveal GA (GA lesion up to the fovea, but not subfoveal) with the lesion's closest border 1725 microns or less from the foveal center in the study eye, as confirmed by the central RC. 12. The entire GA lesion in the study eye must be completely visualized on the macula-centered FAF image, must be able to be imaged in its entirety, and must not be contiguous with any areas of peripapillary atrophy per the Investigator's evaluation and as confirmed by the central RC. 13. A pattern of hyper-autofluorescence in the junctional zone of GA in the study eye must be present as confirmed by the central RC. Fellow Eye Inclusion Criterion: 14. BCVA of 19 letters or more using ETDRS charts in the fellow eye at Screening.

Exclusion Criteria

  1. Current or planned participation in another investigational clinical study or use of any other investigational drugs or devices at least 6 months prior to enrollment or during the study period without prior written Sponsor approval. 2. Previous ophthalmic disease gene therapy or planned participation in any gene therapy clinical study during the study period. 3. Current or planned use of systemic complement inhibitors during the study period. 4. Any ocular or systemic condition that, in the opinion of the Investigator, makes the patient unsuitable for treatment with an investigational drug or that would compromise the safety or efficacy assessments of the study. 5. Treatment with any ocular or systemic medication that is known to be toxic to the lens, retina, or optic nerve (including, but not limited to, aminoglycosides, vancomycin, hydroxychloroquine, interferon, tacrolimus, cisplatin, bis-chloroethyl nitrosourea, carmustine, ethambutol, and tamoxifen) within 90 days prior to Screening or anticipated during the study period. 6. Any previous treatment of pentosan polysulfate (Elmiron®) is exclusionary. 7. Known allergy to fluorescein, povidone iodine, or any ingredients of the study drug or avacincaptad pegol intravitreal solution. 8. Individuals who are currently pregnant, planning to become pregnant, or are nursing at Screening or during the study period. Study Eye Exclusion Criteria: 9. Active ocular or periocular infection in the study eye. 10. Any contraindication to an IVT injection in the study eye. 11. Any media opacity in the study eye that limits visual acuity, clinical visualization of the retina, or retinal imaging as determined by the Investigator. 12. Previous IVT pharmaceutical treatment in the study eye with any agent except Food and Drug Administration (FDA)-approved complement inhibitors and treatment with FDA-approved complement inhibitors within 12 weeks prior to Screening. 13. Any history of incisional retinal surgery in the study eye including but not limited to scleral buckle or vitrectomy. (Retinal laser for a tear or hole 3 months or more prior to Screening is not exclusionary). 14. History of incisional glaucoma surgery including trabeculectomy, tube shunt, or minimally invasive glaucoma surgery in the study eye. (Glaucoma laser procedures performed at least 6 months prior to Screening are not exclusionary). 15. Yttrium aluminum garnet capsulotomy in the study eye within 1 month prior to Screening. 16. Cataract surgery in the study eye planned or expected during the study period. 17. Aphakia with absence of the posterior capsule in the study eye. (Pseudophakia with an open posterior capsule is not exclusionary). 18. Any current evidence or history in the study eye of exudative ("wet") AMD, including any RPE rips or evidence of actively leaking neovascularization anywhere in the retina based on the FA or SD-OCT as assessed per the Investigator's evaluation and confirmed by the central RC. 19. Any clinically significant retinal disease other than AMD except benign degenerative conditions (eg, Cobblestone degeneration) in the study eye. 20. Intraocular surgery in the study eye (including lens replacement surgery) within 3 months prior to Screening. See Exclusion Criteria 12 and 13 pertaining to retinal and glaucoma surgery, respectively. 21. Previous therapeutic radiation (including transpupillary thermotherapy, photodynamic therapy, or external-beam) in the region of the study eye. Fellow Eye Exclusion Criterion: 22. Planned or expected IVT injection in the fellow eye for treatment of GA with agents other than FDA-approved complement inhibitors (pegcetacoplan or avacincaptad pegol IVT solution [Izervay™]) during the study period. Either Eye Exclusion Criteria: 23. Active intraocular inflammation in either eye or a history of uveitis or endophthalmitis in either eye. 24. GA in either eye due to causes other than AMD. 25. Any ophthalmic condition in either eye that is likely to require surgery during the study period.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
ONL1204 Opthalmic solution (1 of 6 Treatment Groups) administered by intravitreal injection 		ONL1204 100 µg administered by intravitreal (IVT) injection every 12 weeks
  • Drug: ONL1204 Opthalmic solution
    Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
Active Comparator
ONL1204 Opthalmic solution (2 of 6 Treatment Groups) administered by intravitreal injection 		ONL1204 200 µg administered by intravitreal (IVT) injection every 12 weeks
  • Drug: ONL1204 Opthalmic solution
    Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
Experimental
ONL1204 Opthalmic solution (3 of 6 Treatment Groups) administered by intravitreal injection 		ONL1204 200 µg administered by intravitreal (IVT) injection every 24 weeks
  • Drug: ONL1204 Opthalmic solution
    Liquid formulation ONL1204 Ophthalmic Solution administered by intravitreal (IVT) injection
Sham Comparator
Sham Comparator (4 of 6 Treatment Groups) 		Sham injection every 12 weeks
  • Other: Sham
    Sham injection
Sham Comparator
Sham Comparator (5 of 6 Treatment Groups) 		Sham injection every 24 weeks
  • Other: Sham
    Sham injection
Active Comparator
Avacincaptad pegol intravitreal solution (6 of 6 Treatment Groups - US ONLY) 		Avacincaptad pegol administered by intravitreal (IVT) injection - (2 mg (0.1 mL of 20 mg/mL solution) once monthly
  • Drug: Avacincaptad Pegol intravitreal solution
    Liquid formulation Avacincaptad Pegol administered by intravitreal (IVT) injection

Recruiting Locations

Associated Retina Consultants
Gilbert, Arizona 85297
Contact:
Study Coordinator

Associated Retina Consultants
Phoenix, Arizona 85020
Contact:
Study Coordinator

Doheny Image Reading Center
Pasadena, California 91103
Contact:
Study Coordinator

Bay Area Retina Associates
Walnut Creek, California 94598
Contact:
Study Coordinator

Retina Consultants of Southern Colorado
Colorado Springs, Colorado 80909-1183
Contact:
Study Coordinator

Retina Group of New England
Waterford, Connecticut 06385
Contact:
Study Coordinator

Florida Retina Institute
Orlando, Florida 32806
Contact:
Study Coordinator

Retina Associates, Ltd.
Elmhurst, Illinois 60126
Contact:
Study Coordinator

Retina Partners Midwest, P.C.
Carmel, Indiana 46032
Contact:
Study Coordinator

Retina Research Institute at New England Retina Consultants
Springfield, Massachusetts 01107
Contact:
Study Coordinator

Associated Retinal Consultants, P.C.
Royal Oak, Michigan 48073
Contact:
Study Coordinator

The Retina Institute
St Louis, Missouri 63128
Contact:
Study Coordinator

Sierra Eye Associates
Reno, Nevada 89502
Contact:
Study Coordinator

Retina Associates of Western NY
Rochester, New York 14620
Contact:
Study Coordinator

Long Island Vitreoretinal Consultants
Westbury, New York 11590
Contact:
Study Coordinator

North Carolina Retina Associates, S.C.
Wake Forest, North Carolina 27587
Contact:
Study Coordinator

Erie Retina Research, LLC (Clinic)
Erie, Pennsylvania 16505
Contact:
Study Coordinator

Charleston Neuroscience Institute
Mt. Pleasant, South Carolina 29464
Contact:
Study Coordinator

Palmetto Retina Center
West Columbia, South Carolina 29169
Contact:
Study Coordinator

Retina Consultants of Texas
Beaumont, Texas 77707
Contact:
Study Coordinator

Retina Consultants of Texas
Bellaire, Texas 77401
Contact:
Study Coordinator

Retina Consultants of Texas
Katy, Texas 77494
Contact:
Study Coordinator

Retina Associates of South Texas, PA
San Antonio, Texas 78240
Contact:
Study Coordinator

Retina Consultants of Texas
San Antonio, Texas 78240
Contact:
Study Coordinator

Retina Consultants of Texas
The Woodlands, Texas 77384
Contact:
Study Coordinator

Pacific Northwest Retina
Bellevue, Washington 98004
Contact:
Study Coordinator

Pacific Northwest Retina, PLLC
Silverdale, Washington 98383
Contact:
Study Coordinator

More Details

NCT ID
NCT06659445
Status
Recruiting
Sponsor
ONL Therapeutics

Study Contact

Study Coordinator
734-412-8787
info@onltherapeutics.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.

For help using this page: trialstoday@researchmatch.org or call 855-514-7001

ResearchMatch is funded in part by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, led by the NIH’s National Center for Advancing Translational Sciences (NCATS), grants UL1TR000445 and 1U54RR032646-01, and grant U24TR001579 from NCATS and the National Library of Medicine. The content of this website is solely the responsibility of ResearchMatch and Vanderbilt University and does not necessarily represent the official views of the NIH, NCATS, or NLM.

Vanderbilt University Medical Center